Media stories about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gilead Sciences earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.3197716945294 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Gilead Sciences, Inc. (GILD) Director Sells $472,064.69 in Stock (americanbankingnews.com)
- Gilead Sciences, Inc. (GILD) Swings under Short-Term Obligation – Stock News Stop (stockmarketstop.com)
- Quebec Expands Patient Access to Chronic Hepatitis C Therapies (finance.yahoo.com)
- Biogen’s Bargain Price May Spur a 14% Stock Gain (finance.yahoo.com)
- Gilead Sciences, Inc. (NASDAQ:GILD) – Price/Earnings to Growth – PEG in Focus – Nasdaq Journal (nasdaqjournal.com)
A number of research firms have issued reports on GILD. Barclays reaffirmed an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a report on Tuesday, March 6th. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Saturday, March 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $94.00 price target on shares of Gilead Sciences in a report on Friday, February 23rd. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 price target (down previously from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $87.75.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the company earned $2.70 earnings per share. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. analysts predict that Gilead Sciences will post 6.21 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. Gilead Sciences’s payout ratio is presently 27.05%.
In other Gilead Sciences news, EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the transaction, the executive vice president now owns 57,114 shares of the company’s stock, valued at $4,512,006. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders sold 430,268 shares of company stock valued at $34,074,395 in the last ninety days. 1.30% of the stock is owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.